Login Register Cart 0
Generic placeholder image

Current Diabetes Reviews

Editor-in-Chief

ISSN (Print): 1573-3998
ISSN (Online): 1875-6417

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Tachykinins Play a Major Role in Micro and Macrovascular Complications in Type 2 Diabetes Patients

Author(s): Faiqah Ramzan, Laila Kiran, Shumaila Noreen Malik and Muhammad Inamullah Malik*

Volume 20, Issue 3, 2024

Published on: 13 July, 2023

Article ID: e050523216590 Pages: 5

DOI: 10.2174/1573399819666230505123844

Price: $65

Abstract

Diabetes Mellitus is a metabolic disorder, which is characterized by an increase in blood glucose levels. The defects in the secretion or action of insulin are the major cause of diabetes. Increase in the blood glucose level exerts a negative effect on the normal functions of the body organs and this leads to the dysfunctions of cells and tissue and causes vascular complications in diabetic patients. Several studies indicate that neuropeptides are released from the neurosensory cells which are mainly known as tachykinins which provoke major vascular complications in diabetic patients. Tachykinins are known as pro-inflammatory peptides which increase vascular complications and vascular permeability. The duration and severity of diabetes disease increase the risk of vascular complication in patients. The aim of this review is to elaborate the role of tachykinins in microvascular and macrovascular complications in diabetic patients. The study concluded that tachykinins increase micro and macrovascular complications in diabetic patients.

[1]
Adeghate E. Diabetes mellitus - multifactorial in aetiology and global in prevalence. Arch Physiol Biochem 2001; 109(3): 197-9.
[http://dx.doi.org/10.1076/apab.109.3.197.11588] [PMID: 11880920]
[2]
IDF Diabetes Atlas 7th ed Brussels, Belgium: International Diabetes Federation. 2015.
[3]
Galkowska H, Olszewski WL, Wojewodzka U, Rosinski G, Karnafel W. Neurogenic factors in the impaired healing of diabetic foot ulcers. J Surg Res 2006; 134(2): 252-8.
[http://dx.doi.org/10.1016/j.jss.2006.02.006] [PMID: 16580687]
[4]
Valencia WM, Florez H. How to prevent the microvascular complications of type 2 diabetes beyond glucose control. BMJ 2017; 356: i6505.
[http://dx.doi.org/10.1136/bmj.i6505] [PMID: 28096078]
[5]
Purga SL, Sidhu M, Farkouh M, Schulman-Marcus J. Recent insights into pharmacologic cardiovascular risk reduction in Type 2 diabetes mellitus. Cardiovasc Drugs Ther 2017; 31(4): 459-70.
[http://dx.doi.org/10.1007/s10557-017-6750-1] [PMID: 28871349]
[6]
Haffner SJ, Cassells H. Hyperglycemia as a cardiovascular risk factor. Am J Med 2003; 115 (Suppl. 8A): 6-11.
[http://dx.doi.org/10.1016/j.amjmed.2003.09.009] [PMID: 14678859]
[7]
Harding S. Extracts from “Concise Clinical Evidence”: Diabetic retinopathy Commentary: Treatment of diabetic retinopathy. BMJ 2003; 326(7397): 1023-5.
[http://dx.doi.org/10.1136/bmj.326.7397.1023] [PMID: 12742927]
[8]
Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984; 102(4): 527-32.
[http://dx.doi.org/10.1001/archopht.1984.01040030405011] [PMID: 6367725]
[9]
Aronin N, Leeman SE, Clements RS Jr. Diminished flare response in neuropathic diabetic patients. Comparison of effects of substance P, histamine, and capsaicin. Diabetes 1987; 36(10): 1139-43.
[http://dx.doi.org/10.2337/diab.36.10.1139] [PMID: 2443407]
[10]
Levy DM, Terenghi G, Gu XH, Abraham RR, Springall DR, Polak JM. Immunohistochemical measurements of nerves and neuropeptides in diabetic skin: Relationship to tests of neurological function. Diabetologia 1992; 35(9): 889-97.
[http://dx.doi.org/10.1007/BF00399938] [PMID: 1397786]
[11]
Amara SG, Jonas V, Rosenfeld MG, Ong ES, Evans RM. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 1982; 298(5871): 240-4.
[http://dx.doi.org/10.1038/298240a0] [PMID: 6283379]
[12]
Rosenfeld MG, Mermod JJ, Amara SG, et al. Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature 1983; 304(5922): 129-35.
[http://dx.doi.org/10.1038/304129a0] [PMID: 6346105]
[13]
Kopaniak MM, Hay JB, Movat HZ. The effect of hyperemia on vascular permeability. Microvasc Res 1978; 15(1): 77-82.
[http://dx.doi.org/10.1016/0026-2862(78)90007-9] [PMID: 634159]
[14]
Barber RP, Vaughn JE, Randall Slemmon J, Salvaterra PM, Roberts E, Leeman SE. The origin, distribution and synaptic relationships of substance P axons in rat spinal cord. J Comp Neurol 1979; 184(2): 331-51.
[http://dx.doi.org/10.1002/cne.901840208] [PMID: 368089]
[15]
Hoyle CHV. Neuropeptide families: Evolutionary perspectives. Regul Pept 1998; 73(1): 1-33.
[http://dx.doi.org/10.1016/S0167-0115(97)01073-2] [PMID: 9537670]
[16]
Steinhoff M, Ständer S, Seeliger S, Ansel JC, Schmelz M, Luger T. Modern aspects of cutaneous neurogenic inflammation. Arch Dermatol 2003; 139(11): 1479-88.
[http://dx.doi.org/10.1001/archderm.139.11.1479] [PMID: 14623709]
[17]
Pernow B, Substance P. Pharmacol Rev 1983; 35(2): 85-141.
[PMID: 6196797]
[18]
Krause JE, Takeda Y, Hershey AD. Structure, functions, and mechanisms of substance P receptor action. J Invest Dermatol 1992; 98 (Suppl. 6): S2-7.
[http://dx.doi.org/10.1111/1523-1747.ep12462082] [PMID: 1316925]
[19]
Louis SM, Jamieson A, Russell NJW, Dockray GJ. The role of substance P and calcitonin gene-related peptide in neurogenic plasma extravasation and vasodilatation in the rat. Neuroscience 1989; 32(3): 581-6.
[http://dx.doi.org/10.1016/0306-4522(89)90281-9] [PMID: 2481241]
[20]
Holzer P, Guth PH. Neuropeptide control of rat gastric mucosal blood flow. Increase by calcitonin gene-related peptide and vasoactive intestinal polypeptide, but not substance P and neurokinin A. Circ Res 1991; 68(1): 100-5.
[http://dx.doi.org/10.1161/01.RES.68.1.100] [PMID: 1702035]
[21]
Vink R, Gabrielian L, Thornton E. The role of Substance P in secondary pathophysiology after traumatic brain injury. Front Neurol 2017; 8: 304-8.
[http://dx.doi.org/10.3389/fneur.2017.00304] [PMID: 28701994]
[22]
Kimura S, Okada M, Sugita Y, Kanazawa I, Munekata E. Novel neuropeptides, neurokinin. ALPHA. and. BETA., isolated from porcine spinal cord. Proc Jpn Acad, Ser B, Phys Biol Sci 1983; 59(4): 101-4.
[http://dx.doi.org/10.2183/pjab.59.101]
[23]
Maggi CA. The mammalian tachykinin receptors. Gen Pharmacol 1995; 26(5): 911-44.
[http://dx.doi.org/10.1016/0306-3623(94)00292-U] [PMID: 7557266]
[24]
Lundberg JM, Saria A. Polypeptide-containing neurons in airway smooth muscle. Annu Rev Physiol 1987; 49(1): 557-72.
[http://dx.doi.org/10.1146/annurev.ph.49.030187.003013] [PMID: 3551812]
[25]
Kangawa K, Minamino N, Fukuda A, Matsuo H. Neuromedin K and B: Novel neuropeptides with smooth muscle stimulant activity identified in pig spinal cord. In: Munekata E, Ed proceedings of the 21st Symposium on peptide chemistry. Osaka. 1983; p. 309-14.
[26]
Frossard N, Rhoden KJ, Barnes PJ. Influence of epithelium on guinea pig airway responses to tachykinins: Role of endopeptidase and cyclooxygenase. J Pharmacol Exp Ther 1989; 248(1): 292-8.
[PMID: 2464059]
[27]
Lundberg JM. Pharmacology of cotransmission in the autonomic nervous system: Integrative aspects on amines, neuropeptides, adenosine triphosphate, amino acids and nitric oxide. Pharmacol Rev 1996; 48(1): 113-78.
[PMID: 8685245]
[28]
Toda M, Suzuki T, Hosono K, et al. Roles of calcitonin gene-related peptide in facilitation of wound healing and angiogenesis. Biomed Pharmacother 2008; 62(6): 352-9.
[http://dx.doi.org/10.1016/j.biopha.2008.02.003] [PMID: 18430544]
[29]
Tonelli M, Keech A, Shepherd J, et al. Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol 2005; 16(12): 3748-54.
[http://dx.doi.org/10.1681/ASN.2005070779] [PMID: 16251235]
[30]
Steinhoff MS, von Mentzer B, Geppetti P, Pothoulakis C, Bunnett NW. Tachykinins and their receptors: Contributions to physiological control and the mechanisms of disease. Physiol Rev 2014; 94(1): 265-301.
[http://dx.doi.org/10.1152/physrev.00031.2013] [PMID: 24382888]
[31]
Delgado AV, McManus AT, Chambers JP. Exogenous administration of substance P enhances wound healing in a novel skin-injury model. Exp Biol Med 2005; 230(4): 271-80.
[http://dx.doi.org/10.1177/153537020523000407] [PMID: 15792949]
[32]
Krentz AJ, Clough G, Byrne CD. Interactions between microvascular and macrovascular disease in diabetes: Pathophysiology and therapeutic implications. Diabetes Obes Metab 2007; 9(6): 781-91.
[http://dx.doi.org/10.1111/j.1463-1326.2007.00670.x] [PMID: 17924862]
[33]
Caselli A, Rich J, Hanane T, Uccioli L, Veves A. Role of C-nociceptive fibers in the nerve axon reflex-related vasodilation in diabetes. Neurology 2003; 60(2): 297-300.
[http://dx.doi.org/10.1212/01.WNL.0000040250.31755.F9] [PMID: 12552048]
[34]
Anand P. Nerve growth factor regulates nociception in human health and disease. Br J Anaesth 1995; 75(2): 201-8.
[http://dx.doi.org/10.1093/bja/75.2.201] [PMID: 7577254]
[35]
Komaru T, Kanatsuka H, Shirato K. Coronary microcirculation. Pharmacol Ther 2000; 86(3): 217-61.
[http://dx.doi.org/10.1016/S0163-7258(00)00057-7] [PMID: 10882810]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy